CD19 has demonstrated value as a target in B‐cell NHL, particularly in patients with relapsed or refractory disease, as demonstrated by the efficacy profile of the currently available anti‐CD19 therapies. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.